The pharmaceutical services industry has attracted billions of dollars from private equity investors over the years. Now, uncertainty associated with the new presidential administration could shake up some buyout funds’ largest bets. Investors are concerned about a disruption to the clinical trial process, the possibility of which has been top of mind for many since President-elect Donald Trump revealed plans to nominate Robert F. Kennedy Jr., a vaccine skeptic, to head the Department of Health and Human Services. Jeffrey Jay, founder and managing partner at investment manager Great Point Partners and a healthcare investor for the past 30 years, said mounting vaccine scrutiny could raise standards for running clinical trials and eventually decrease trial volume.
Read the full article: RFK Jr. Nomination Dents PE Confidence in CRO Market //
Source: https://pitchbook.com/news/articles/rfk-jr-nomination-dents-pe-confidence-in-cro-market